BusinessTeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of HematologyBy Nasdaq OMXDec 11, 2017, 1:00 PM UTC
BusinessActinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic MutationsBy Nasdaq OMXDec 5, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology PlatformBy Nasdaq OMXNov 29, 2017, 12:32 PM UTC
BusinessActinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology PlatformBy Nasdaq OMXNov 14, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology PlatformBy Nasdaq OMXNov 1, 2017, 1:05 PM UTC
BusinessActinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid LeukemiaBy Nasdaq OMXOct 4, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council MeetingBy Nasdaq OMXSep 20, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual MeetingBy Nasdaq OMXSep 13, 2017, 11:30 AM UTC
